Revance Therapeutics, Inc.
USD3.65
+0.00 (+0.00%)
CEO
Mark J. Foley
IPO Date
2014-02-06
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$3.65
Prev. Close
$3.65
Day Low
$3.65
Day High
$3.65
52W Low
$2.30
52W High
$7.56
Market Cap
$0.38B
| -3.8 |
| 31 Dec 2021 | FY | 69.9% | -368.7% | -418.9% | -54.0% | 4.74 | 3.66 | -3.8 |
| 31 Dec 2020 | FY | 68.9% | -1840.7% | -75.4% | -39.2% | 0.57 | 7.38 | -5.8 |
| 31 Dec 2019 | FY | -24805.8% | -37824.9% | -69.3% | -45.9% | 0.13 | 7.24 | -4.5 |
| 31 Dec 2018 | FY | -2380.6% | -3823.2% | -97.9% | -63.0% | 0.00 | 6.50 | -5.1 |
| 31 Dec 2017 | FY | 100.0% | -46025.6% | -44.9% | -40.8% | 0.01 | 13.65 | -8.9 |
| 31 Dec 2016 | FY | 100.0% | -29756.7% | -50.4% | -43.7% | 0.03 | 9.81 | -6.5 |
| 31 Dec 2015 | FY | -565.0% | -24492.0% | -29.0% | -26.6% | 0.03 | 21.10 | -11.3 |
| 31 Dec 2014 | FY | 100.0% | -16427.4% | -35.7% | -32.7% | 0.02 | 16.87 | -5.2 |
| -1.8 |
| 31 Mar 2024 | Q1 | 67.5% | -102.3% | 53.9% | -10.5% | -4.82 | 5.37 | -2.0 |
| 31 Dec 2023 | Q4 | 72.9% | -79.8% | 36.7% | -11.6% | -3.16 | 3.80 | -3.6 |
| 30 Sept 2023 | Q3 | 65.8% | -248.7% | 132.9% | -26.5% | -4.76 | 4.73 | -1.8 |
| 30 Jun 2023 | Q2 | 63.3% | -115.8% | -251.3% | -11.3% | 16.14 | 5.12 | -7.9 |
| 31 Mar 2023 | Q1 | 67.2% | -133.9% | 247.6% | -12.1% | -16.34 | 4.14 | -9.9 |
| 31 Dec 2022 | Q4 | 52.9% | -289.6% | -1147.2% | -24.8% | 33.21 | 4.95 | -2.6 |
| 30 Sept 2022 | Q3 | 63.0% | -291.9% | -58.1% | -11.9% | 2.94 | 5.56 | -5.8 |
| 30 Jun 2022 | Q2 | 66.4% | -216.8% | 2337.4% | -10.9% | -166.36 | 3.38 | -3.9 |